drugset / Trial / NCT01253902

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01253902

Phase 4 Completed 164 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.

Timeline

Start
2010-12
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified 0.01 % Topical
Comparator Latanoprost Small molecule 0.005 % Topical
Comparator Travoprost Other / unclassified 0.004 % Topical